RU2705156C2 - Таблетки, содержащие большую дозу рукапариба - Google Patents

Таблетки, содержащие большую дозу рукапариба Download PDF

Info

Publication number
RU2705156C2
RU2705156C2 RU2017109139A RU2017109139A RU2705156C2 RU 2705156 C2 RU2705156 C2 RU 2705156C2 RU 2017109139 A RU2017109139 A RU 2017109139A RU 2017109139 A RU2017109139 A RU 2017109139A RU 2705156 C2 RU2705156 C2 RU 2705156C2
Authority
RU
Russia
Prior art keywords
tablet
active pharmaceutical
contained
pharmaceutical ingredient
range
Prior art date
Application number
RU2017109139A
Other languages
English (en)
Russian (ru)
Other versions
RU2017109139A3 (enExample
RU2017109139A (ru
Inventor
Джеффри ЭТТЕР
Original Assignee
Кловис Онколоджи, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кловис Онколоджи, Инк. filed Critical Кловис Онколоджи, Инк.
Publication of RU2017109139A publication Critical patent/RU2017109139A/ru
Publication of RU2017109139A3 publication Critical patent/RU2017109139A3/ru
Application granted granted Critical
Publication of RU2705156C2 publication Critical patent/RU2705156C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017109139A 2014-08-22 2015-08-17 Таблетки, содержащие большую дозу рукапариба RU2705156C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US62/040,849 2014-08-22
US201562101739P 2015-01-09 2015-01-09
US62/101,739 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (3)

Publication Number Publication Date
RU2017109139A RU2017109139A (ru) 2018-09-24
RU2017109139A3 RU2017109139A3 (enExample) 2019-03-06
RU2705156C2 true RU2705156C2 (ru) 2019-11-05

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017109139A RU2705156C2 (ru) 2014-08-22 2015-08-17 Таблетки, содержащие большую дозу рукапариба

Country Status (22)

Country Link
US (3) US9987285B2 (enExample)
EP (1) EP3182975B1 (enExample)
JP (3) JP6574477B2 (enExample)
KR (2) KR20170043597A (enExample)
CN (2) CN113209033A (enExample)
AU (2) AU2015305696B2 (enExample)
BR (1) BR112017000865A2 (enExample)
CA (1) CA2955495C (enExample)
DK (1) DK3182975T3 (enExample)
ES (1) ES3048688T3 (enExample)
FI (1) FI3182975T3 (enExample)
HR (1) HRP20251484T1 (enExample)
IL (1) IL249946B (enExample)
LT (1) LT3182975T (enExample)
MX (1) MX367260B (enExample)
NZ (1) NZ728392A (enExample)
PT (1) PT3182975T (enExample)
RS (1) RS67356B1 (enExample)
RU (1) RU2705156C2 (enExample)
SG (1) SG11201700265VA (enExample)
SI (1) SI3182975T1 (enExample)
WO (1) WO2016028689A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383378B (es) 2014-02-05 2025-03-13 Merck Sharp & Dohme Llc Formulación de tableta para compuestos activos de péptido relacionado con el gen de calcitonina.
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
ES3048688T3 (en) 2014-08-22 2025-12-11 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
US10875870B2 (en) 2017-01-24 2020-12-29 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
JP7269227B2 (ja) 2017-09-26 2023-05-08 テサロ， インコーポレイテッド ニラパリブ処方物
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
BR112020013672A2 (pt) 2018-01-05 2020-12-01 Cybrexa 1, Inc. compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) * 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
BR112022000337A2 (pt) 2019-07-10 2022-04-12 Cybrexa 2 Inc Conjugados de peptídeos de citotoxinas como terapêuticos
AU2020311925A1 (en) 2019-07-10 2022-02-03 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
WO2021220120A1 (en) 2020-04-28 2021-11-04 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
HRP20251324T1 (hr) 2020-07-14 2025-12-05 Assia Chemical Industries Ltd. Oblici soli rukapariba u krutom stanju
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase
AU2022353124A1 (en) 2021-09-27 2024-04-11 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
EP4429636A1 (en) * 2021-11-10 2024-09-18 Crititech, Inc. Rucaparib particles and uses thereof
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136883A1 (en) * 2008-04-09 2011-06-09 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
US20120302550A1 (en) * 2010-02-12 2012-11-29 Pfizer Inc. Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360003C (en) 1999-01-11 2012-07-10 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
WO2004087713A1 (en) 2003-03-31 2004-10-14 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ES2339663T3 (es) 2003-07-25 2010-05-24 Cancer Research Technology Limited Inhibidores de parp triciclicos.
JP4966858B2 (ja) 2004-09-22 2012-07-04 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害薬の製造方法
ES2382950T3 (es) 2004-09-22 2012-06-14 Pfizer, Inc. Formas polimorfas de la sal de fosfato de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-acepin[5,4,3-cd]indol-6-ona
NZ553295A (en) 2004-09-22 2010-04-30 Pfizer Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor
AU2013243291B2 (en) 2012-04-05 2018-02-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and combination therapies thereof
ES3048688T3 (en) 2014-08-22 2025-12-11 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136883A1 (en) * 2008-04-09 2011-06-09 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
US20120302550A1 (en) * 2010-02-12 2012-11-29 Pfizer Inc. Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
RU2570198C2 (ru) * 2010-02-12 2015-12-10 Пфайзер Инк. СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА

Also Published As

Publication number Publication date
NZ728392A (en) 2023-06-30
RS67356B1 (sr) 2025-11-28
KR102803917B1 (ko) 2025-05-07
WO2016028689A1 (en) 2016-02-25
IL249946A0 (en) 2017-03-30
EP3182975A4 (en) 2018-04-18
JP7127101B2 (ja) 2022-08-29
RU2017109139A3 (enExample) 2019-03-06
EP3182975B1 (en) 2025-10-01
CA2955495A1 (en) 2016-02-25
BR112017000865A2 (pt) 2017-12-05
US20180200260A1 (en) 2018-07-19
IL249946B (en) 2020-05-31
PT3182975T (pt) 2025-10-28
HRP20251484T1 (hr) 2026-01-02
JP2020002149A (ja) 2020-01-09
LT3182975T (lt) 2025-11-25
US20160051561A1 (en) 2016-02-25
SG11201700265VA (en) 2017-02-27
CN113209033A (zh) 2021-08-06
FI3182975T3 (fi) 2025-11-13
JP2021038242A (ja) 2021-03-11
KR20170043597A (ko) 2017-04-21
ES3048688T3 (en) 2025-12-11
MX2017001540A (es) 2017-05-11
AU2019272064A1 (en) 2019-12-19
DK3182975T3 (da) 2025-10-20
JP6797980B2 (ja) 2020-12-09
EP3182975A1 (en) 2017-06-28
AU2015305696B2 (en) 2019-08-29
SI3182975T1 (sl) 2025-12-31
AU2015305696A1 (en) 2017-02-02
KR20230097211A (ko) 2023-06-30
RU2017109139A (ru) 2018-09-24
JP2017525712A (ja) 2017-09-07
US20190099430A1 (en) 2019-04-04
CN106794185A (zh) 2017-05-31
JP6574477B2 (ja) 2019-09-11
US10130636B2 (en) 2018-11-20
CA2955495C (en) 2023-09-19
AU2019272064B2 (en) 2021-11-18
US9987285B2 (en) 2018-06-05
MX367260B (es) 2019-08-12

Similar Documents

Publication Publication Date Title
RU2705156C2 (ru) Таблетки, содержащие большую дозу рукапариба
RU2456989C2 (ru) Твердые лекарственные формы, содержащие тадалафил
KR100634253B1 (ko) 초강력 붕해제를 사용한 고속-용해 에파비렌즈 캡슐 또는정제 및 그의 제조 방법
KR100202154B1 (ko) 파라세타몰 및 돔페리돈을 함유한 필름 피복 정제
WO2016020080A1 (en) Pharmaceutical compositions of edoxaban
TWI418370B (zh) 溶出安定性製劑
KR20160002177A (ko) 오셀타미비어 유리염기를 포함하는 약학 조성물
JP2016539110A (ja) イソニアジドの顆粒およびリファペンチンの顆粒を含む分散性錠剤の形態の抗結核性の安定な医薬組成物ならびにその製造方法
JP7336528B2 (ja) ネフォパムおよびアセトアミノフェンを含む薬学的組成物の製造方法、およびそれによって得られる薬学的組成物
EP3079672B1 (en) Pharmaceutical composition comprising a pharmaceutically acceptable salt of rasagiline
EP3784218A1 (en) Tablet compositions comprising abiraterone acetate
KR20160140567A (ko) 오셀타미비어 유리염기를 포함하는 약학 조성물
EP4401708A1 (en) Pharmaceutical composition of bempedoic acid
HK1232807A1 (en) High dosage strength tablets of rucaparib
HK1232807B (en) High dosage strength tablets of rucaparib
EP3272348A1 (en) Pharmaceutical composition comprising idelalisib